STEP61 inhibitors, already effective in AD models, represent a promising convergence point because STEP61 dysregulation appears in both Aβ-driven LTD and FMRP-deficient synapses (Goebel-Goody and Lombroso, 2012; Bagwe et al., 2023). The gene discussed is FMR1; the disease is Alzheimer disease.